
Nvidia is likely to seek EU antitrust approval for its US$54 billion takeover of British chip designer Arm early next month, with regulators expected to launch a full-scale investigation after a preliminary review, people familiar with the matter said.
The world’s biggest maker of graphics and AI chips announced the Arm deal last year, sparking an immediate backlash in the semiconductor industry.
Arm has long been a neutral player licensing key intellectual property to customers who are otherwise intense rivals, including Qualcomm, Samsung Electronics, and Apple.
However, Nvidia stated it has garnered the support of Arm customers Broadcom, MediaTek, and Marvell, according to a presentation on its website.
A request to the European Commission for approval of the deal will kick off a 25-working day preliminary review. Nvidia is unlikely to offer concessions during this period, the sources said, which will then prompt a 90-working day full-scale EU investigation.
Related: UK’s CMA Says Nvidia’s Takeover Of Arm Raises Competition Concerns
Sources previously told Reuters in June that Nvidia may not be able to meet a March 2022 deadline for closing its deal due to European regulators’ reluctance to consider the case until after the summer holidays.
The Financial Times reported earlier that the European Union was set to launch a formal competition probe into the planned takeover early next month.
Britain’s competition regulator announced last week that the deal could damage competition and weaken rivals, and required a further lengthy investigation.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas